Contraindicated (1)bortezomib will improve the amount or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or reasonable CYP2C19 inhibitors may well enhance mavacamten systemic exposure, leading to heart failure as a consequence of systolic dysfunction. If you will find any glitches in execution: the error messages may https://euripidesc332pbo6.sharebyblog.com/profile